Cogent Biosciences Inc.
| NASDAQ: COGT | Healthcare / Biotechnology / USA |
| 9.49 | -0.1000 | -1.04% | Vol 407.01K | 1Y Perf -35.38% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 9.05 | ASK | 10.33 | ||
| Open | 9.60 | Previous Close | 9.59 | ||
| Pre-Market | - | After-Market | 9.60 | ||
| - - | 0.11 1.16% |
| Target Price | 22.14 | Analyst Rating | Strong Buy 1.11 | |
| Potential % | 133.30 | Finscreener Ranking | ★★ 46.38 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 47.51 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★+ 40.54 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 4.03 | Earnings Rating | Buy | |
| Market Cap | 811.07M | Earnings Date | 13th Nov 2023 | |
| Alpha | 0.04 | Standard Deviation | 0.67 | |
| Beta | 1.73 |
Today's Price Range 9.239.60 | 52W Range 9.2315.68 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -2.24% | ||
| 1 Month | -26.12% | ||
| 3 Months | -19.82% | ||
| 6 Months | -9.44% | ||
| 1 Year | -35.38% | ||
| 3 Years | 2.46% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -129.38 | |||
ROE last 12 Months | -74.73 | |||
ROA (5Y Avg) | -25.50 | |||
ROA last 12 Months | -45.90 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -70.90 | |||
Return on invested Capital Q | -14.06 | |||
Return on invested Capital Y | -20.22 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -5.00 | ||||
| 3.90 | ||||
| 1.12K | ||||
| - | ||||
| -9.30 | ||||
| -2.14 | ||||
| 3.90 | ||||
| 3.21 | ||||
| 670.49M | ||||
| Forward PE | -4.75 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 12.30 | ||||
| 12.60 | ||||
| 0.06 | ||||
| 0.09 | ||||
| - | ||||
| Leverage Ratio | 1.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -31 649.70 | ||||
| -31 595.20 | ||||
| -540.40 | ||||
| -48.98 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| -44.18 | ||||
| -23.18 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.53 | -0.59 | -11.32 |
| Q01 2023 | -0.58 | -0.54 | 6.90 |
| Q04 2022 | -0.50 | -0.56 | -12.00 |
| Q03 2022 | -0.51 | -0.50 | 1.96 |
| Q02 2022 | -0.64 | -0.71 | -10.94 |
| Q01 2022 | -0.53 | -0.68 | -28.30 |
| Q04 2021 | -0.55 | -0.61 | -10.91 |
| Q03 2021 | -0.43 | -0.48 | -11.63 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.50 | 3.85 | Positive |
| 12/2023 QR | -0.50 | 3.85 | Positive |
| 12/2023 FY | -2.13 | -0.47 | Negative |
| 12/2024 FY | -2.05 | 0.49 | Positive |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.50 |
| Estimates Count | 6 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 407.01K |
| Shares Outstanding | 85.47K |
| Shares Float | 81.11M |
| Trades Count | 5.80K |
| Dollar Volume | 3.83M |
| Avg. Volume | 630.52K |
| Avg. Weekly Volume | 474.82K |
| Avg. Monthly Volume | 771.48K |
| Avg. Quarterly Volume | 645.27K |
Cogent Biosciences Inc. (NASDAQ: COGT) stock closed at 9.59 per share at the end of the most recent trading day (a 0.42% change compared to the prior day closing price) with a volume of 592.59K shares and market capitalization of 811.06M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 72 people. Cogent Biosciences Inc. CEO is Andrews R. Robbins.
The one-year performance of Cogent Biosciences Inc. stock is -35.38%, while year-to-date (YTD) performance is -17.04%. COGT stock has a five-year performance of %. Its 52-week range is between 9.23 and 15.68, which gives COGT stock a 52-week price range ratio of 4.03%
Cogent Biosciences Inc. currently has a PE ratio of -5.00, a price-to-book (PB) ratio of 3.90, a price-to-sale (PS) ratio of 1 116.28, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -45.90%, a ROC of -70.90% and a ROE of -74.73%. The company’s profit margin is -48.98%, its EBITDA margin is -31 595.20%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cogent Biosciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. Cogent Biosciences Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Cogent Biosciences Inc. is Strong Buy (1.11), with a target price of $22.14, which is +133.30% compared to the current price. The earnings rating for Cogent Biosciences Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cogent Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cogent Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.84, ATR14 : 0.48, CCI20 : -87.10, Chaikin Money Flow : 0.02, MACD : -0.66, Money Flow Index : 2.55, ROC : -18.45, RSI : 28.61, STOCH (14,3) : 13.24, STOCH RSI : 0.40, UO : 51.42, Williams %R : -86.76), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cogent Biosciences Inc. in the last 12-months were:
Cogent Biosciences Inc.
Cogent Biosciences Inc is a biotechnology company. The company is engaged in the development of solutions to treat genetically driven diseases.
CEO: Andrews R. Robbins
Telephone: +1 617 945-5576
Address: 200 Cambridge Park Drive, Cambridge 02140, MA, US
Number of employees: 72
TipRanks News for COGT
Tue, 18 Jul 2023 05:35 GMT Cogent Biosciences (COGT) Receives a Buy from SVB Securities
- TipRanks. All rights reserved.
